Akademik Veri Yönetim Sistemi
UNION OF THRACE UNIVERSITIES V. INTERNATIONAL HEALTH SCIENCES CONGRESS 2022, Balıkesir, Türkiye, 1 - 02 Aralık 2022, ss.220
In the clinic, ulcerative colitis (UC) treatment is usually carried out with pharmacological agents such as immunosuppressants and antibiotics. However, as a result of long-term use of these agents, serious side effects can be seen and this leads to a decrease in the quality of life of the UC patients. Various administrations that can be an alternative to pharmacological treatment in UC are subject to more and more studies every day. One of these innovative administrations is fecal microbiota transplantation (FMT). In this procedure, feces samples taken from healthy donors are administered to UC patients in various ways (e.g. enema or colonoscopy) after some procedures. The purpose of FMT is to reconvert the intestinal microbiota pattern, which exhibits dysbiotic character in the presence of UC, to a healthy microbial composition. Because the presence of dysbiosis significantly increases the release level of inflammatory cytokines, which is the biggest obstacle to remission in UC. In various clinical studies in the literature, it has been shown that FMT administration increases the clinical remission rates of UC and leads to significant decreases in clinical scoring that measures the severity of the disease. In some RCTs involving FMT, it was determined that the density of bacteria in the genus "Clostridium cluster IV" and "Clostridium cluster XIVa", which are thought to have a role in the formation of UC, decreased. In the treatment of UC, FMT stands out as an alternative therapeutic administration due to its low cost and less side effects compared to pharmacological treatment. However, it has been determined that the number of RCTs is limited in the literature, and the frequency and duration of administration vary considerably. Therefore, more RCTs are needed to clarify the effectiveness of the FMT administration.